Selinexor combined with R-CHOP achieved a high response rate in newly diagnosed double/triple-hit lymphoma.
Blood AdvSep 12, 2026
Clinical ResearchOncology (Medical)
Cong Li, Xi Chen, Jieyu Xu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II clinical trial evaluated the combination of selinexor with R-CHOP in 13 patients with newly diagnosed double-hit and triple-hit lymphoma. The study found a 100% overall response rate, with 76.9% achieving complete response. At a median follow-up of 25.4 months, the 2-year progression-free survival and overall survival rates were 67.7% and 67.1%, respectively.
Key findings
- Overall response rate was 100%, with 76.9% achieving complete response.
- At 25.4 months median follow-up, 2-year progression-free survival was 67.7%.
- Posttreatment cfDNA negativity was achieved in 72.7% of patients in complete response.
Why it matters
The findings suggest that combining selinexor with R-CHOP may enhance treatment efficacy in aggressive lymphoma subtypes, which typically have poor prognoses. Understanding response rates and safety profiles is crucial for optimizing therapy in this patient population.